Attached files
file | filename |
---|---|
EX-23.1 - EX-23.1 - Arcus Biosciences, Inc. | d548480dex231.htm |
EX-5.1 - EX-5.1 - Arcus Biosciences, Inc. | d548480dex51.htm |
As filed with the Securities and Exchange Commission on March 14, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form S-1
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
Arcus Biosciences, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 2834 | 47-3898435 | ||
(State or Other Jurisdiction of Incorporation or Organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward, CA 94545
(510) 694-6200
(Address, including zip code and telephone number, including area code, of registrants principal executive offices)
Terry Rosen, Ph.D.
Chief Executive Officer
Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward, CA 94545
(510) 694-6200
(Name, address, including zip code and telephone number, including area code, of agent for service)
Copies to:
Marcia A. Hatch Heidi E. Mayon Richard C. Blake Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP 1200 Seaport Blvd. Redwood City, CA 94063 (650) 321-2400 |
Jennifer Jarrett Chief Business and Financial Officer Arcus Biosciences, Inc. 3928 Point Eden Way Hayward, CA 94545 (510) 694-6200 |
Kenneth L. Guernsey Jonie I. Kondracki Charles S. Kim Cooley LLP 101 California Street, 5th Floor San Francisco, CA 94111 (415) 693-2000 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-223086
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Non-accelerated filer | ☒ (Do not check if a smaller reporting company) | Accelerated filer | ☐ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of Each Class of Securities to be Registered |
Amount to be |
Proposed Maximum Offering Price Per Share |
Proposed Offering Price(1)(2) |
Amount of Registration Fee(2)(3) | ||||
Common Stock, $0.0001 par value per share |
1,035,000 | $15.00 | $15,525,000 | $1,933 | ||||
| ||||||||
|
(1) | Represents only the additional number of shares being registered and includes an additional 135,000 shares that the underwriters have an option to purchase. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-223086), as amended (the Registration Statement), and is based on the initial public offering price. |
(2) | The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended (the Securities Act). |
(3) | The Registrant previously registered 8,165,000 shares of its common stock, for which the fee was $15,249, on the Registration Statement, which was declared effective by the Securities and Exchange Commission on March 14, 2018. In accordance with Rule 462(b) under the Securities Act, an additional 1,035,000 shares of common stock are hereby registered. |
This Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended.
EXPLANATORY NOTE AND INCORPORATION OF
CERTAIN INFORMATION BY REFERENCE
Pursuant to Rule 462(b) under the Securities Act of 1933, as amended (Securities Act), Arcus Biosciences, Inc. (Registrant) is filing this Registration Statement on Form S-1 (this Registration Statement) with the Securities and Exchange Commission (Commission). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-1, as amended (File No. 333-223086) (the Prior Registration Statement), which the Registrant originally filed with the Commission on February 16, 2018, and subsequently amended on March 5, 2018 and March 9, 2018, and which the Commission declared effective on March 14, 2018.
The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate number of shares of common stock, par value $0.0001 per share, offered by the Registrant by 1,035,000 shares, 135,000 of which are subject to purchase upon exercise of the underwriters option to purchase additional shares of the Registrants common stock. The additional shares that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Prior Registration Statement. The information set forth in the Prior Registration Statement, including all amendments and exhibits thereto, is incorporated by reference herein.
The required opinion and consents are listed on the Exhibit Index attached hereto and filed herewith.
EXHIBIT INDEX
* | Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Hayward, State of California, on the 14th day of March, 2018.
ARCUS BIOSCIENCES, INC. | ||
By: | /s/ Jennifer Jarrett | |
Jennifer Jarrett Chief Business Officer and Chief Financial Officer |
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Name | Title | Date | ||
* Terry Rosen, Ph.D. |
Chief Executive Officer and Director (Principal Executive Officer) |
March 14, 2018 | ||
* Juan Carlos Jaen, Ph.D. |
President and Director | March 14, 2018 | ||
/s/ Jennifer Jarrett Jennifer Jarrett |
Chief Business Officer and Chief Financial Officer (Principal Financial Officer) |
March 14, 2018 | ||
* Steven Chan |
Principal Accounting Officer | March 14, 2018 | ||
* Yasunori Kaneko, M.D. |
Director | March 14, 2018 | ||
* Kathryn Falberg |
Director | March 14, 2018 | ||
* David William Beier |
Director | March 14, 2018 |
*By: | /s/ Jennifer Jarrett | |
Jennifer Jarrett Attorney-in-fact |